at a purchase price of $31.00 per share. By the expiration of the present, 140,550,153 shares of common stock of Amylin were tendered and not withdrawn in the tender offer. Most of such shares have already been accepted for payment relative to the terms of the tender present. The tender offer expired at 5:00 p.m., NEW YORK time, on 7 August, 2012. As a total result of the tender present, Bristol-Myers Squibb owns now, together with its subsidiaries, 85 around.55 percent of the outstanding shares of Amylin.The acquisition of Molegro supports CLC bio’s strategy of continuously growing their bioinformatics offerings beyond Next Generation Sequencing, as well as in bioinformatics regions of value to their customer bottom.’ ‘Since 2005, Molegro has demonstrated the capability to develop and support excellent molecular docking products. We anticipate adding the very talented folks from Molegro to our team at CLC bio.’ claims CEO at CLC bio, Thomas Knudsen, and adds, ‘This acquisition underlines our dedication to look for the most viable usually methods to enhance our evaluation platform for the advantage of our customers.’ In the arriving years, CLC bio shall invest significant resources in to the continued advancement of the acquired protein-ligand docking and data modeling software.